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Abstract: The G protein-coupled receptor (GPCR) superfamily is a large group of membrane pro-
teins which, because of their vast involvement in cell signalling pathways, are implicated in a pleth-
ora of disease states and are therefore considered to be key drug targets. Despite advances in tech-
niques to study these receptors, current prophylaxis is often limited due to the challenging nature 
of their dynamic, complex structures. Greater knowledge and understanding of their intricate struc-
tural rearrangements will therefore undoubtedly aid structure-based drug design against GPCRs. 
Disciplines such as anthropology and palaeontology often use geometric morphometrics to meas-
ure variation between shapes and we have therefore applied this technique to analyse GPCR struc-
tures in a three-dimensional manner, using principal component analysis. Our aim was to create a 
novel system able to discriminate between GPCR structures and discover variation between them, 
correlated with a variety of receptor characteristics. This was conducted by assessing shape changes 
at the extra- and intracellular faces of the transmembrane helix bundle, analysing the XYZ coordi-
nates of the amino acids at those positions. We have demonstrated that GPCR structures can be 
classified based on characteristics such as activation state, bound ligands and fusion proteins, with 
the most significant results focussed at the intracellular face. Conversely, our analyses provide evi-
dence that thermostabilising mutations do not cause significant differences when compared to non-
mutated GPCRs. We believe that this is the first time geometric morphometrics has been applied to 
membrane proteins on this scale, and believe it can be used as a future tool in sense-checking newly 
resolved structures and planning experimental design. 
Keywords: GPCR; ligand; activity; thermostabilised; recombinant; structure; geometric morpho-
metrics; principal component analysis 
 
1. Introduction 
G protein-coupled receptors (GPCRs) are one of the most widely studied families of 
membrane proteins in the human genome due to their extensive involvement in a pleth-
ora of cell signaling pathways [1]. These seven-transmembrane eukaryotic receptors con-
tribute to the normal function of a cell but can also be responsible for a widespread variety 
of disease states. While approximately 40% of all drugs target these receptors [2], this must 
be contrasted with a relatively low coverage of the GPCR family overall (around 19%), 
leaving many conditions with little to no prophylactic options [3]. Advances in drug de-
sign and discovery are therefore needed to expand this coverage; further understanding 
of the structure–function relationship of GPCRs will aid with the development of or-
thosteric and allosteric ligands against these receptors, widening the pool of potentially 
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druggable GPCRs [4]. This paper therefore presents a novel application of a mathematical 
technique, geometric morphometrics with principal component analysis, to further en-
hance the field’s knowledge and understanding of GPCR structures. 
GPCRs are typically composed of three domains as shown in Figure 1; the N terminus 
which is extracellular, the transmembrane (TM) domain and the C terminus which is in-
tracellular. These are connected by three extra- and three intracellular loops [5]. While the 
TM domain always contains seven alpha-helices and the C terminus is relatively short, 
the N terminus varies in size depending on the classification of the receptor. As the N 
terminus can form a part of the location of orthosteric ligand binding, the ligands also 
vary in size and characteristic, ranging between ions and proteins [6]. Referring to the 
original system of classification, there are six main GPCR families (named A–F), as sum-
marised in Table 1. Additionally, the alternative GRAFS system describes the main five 
vertebrate GPCR families: (G)lutamate, (R)hodopsin, (A)dhesion, (F)rizzled/Taste2 and 
(S)ecretin [7]. This paper will continue to use the classical system, alongside naming the 
appropriate receptor sub-groups (for example, the neurotensin receptors within family 
A). 
   
(a) (b) (c) 
Figure 1. The typical structure of a G protein-coupled receptor (GPCR). (a) A two-dimensional representation of a GPCR 
showing its extracellular N terminus (NT), seven transmembrane helices (TM1-7, multicoloured), three extracellular loops 
(ECL1-3), three intracellular loops (ICL1-3) and intracellular C terminus (CT). (b) A three-dimensional representation of 
the transmembrane bundle, with helices labelled 1–7 and intracellular recruitment of a G protein (yellow circles). (c) An 
example of a resolved GPCR crystal structure for context (β2AR receptor, PDB code 6PS0) [8]. 
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Table 1. A classification summary of the six G protein-coupled receptor (GPCR) families [7]. GPCRs are typically grouped 
based on sequence homology and functional similarity, though many are still considered ‘orphans’—receptors of un-
known function or classification. Family D and E (found in fungi and slime moulds) are not understood as well as the 
other four families, due to their limited application to human prophylaxis; mammalian receptors have understandably 
taken priority with structural studies and pharmaceutical research. 
Receptor Family Description Features Ligand Examples 
A Rhodopsin-like 
Lacks a substantial extracellular domain; 
thus native ligands bind directly to the 
transmembrane domain 
Light, small molecules, peptides, proteins 
(e.g., opioids, vasopressin, neurotensin, epi-
nephrine, etc.) 
B Secretin-like 
Flexible, folded extracellular domain 
containing a hormone binding motif 
Peptide hormones (e.g., calcitonin, gluca-




Dynamic extracellular domain contain-
ing a venus flytrap module 
Ions and small molecules (e.g., gamma-
amino butyric acid, glutamate, calcium, 
etc.) 
D 
Fungal mating pheromone 
receptors 
Activates MAPK signals to induce cell-
cell fusion forming a diploid zygote 
Cell membrane mating factors (alpha-factor 
and a-factor) 




Beginning of Wnt and Hedgehog signal-
ling pathways 
Wnt protein ligands, Smoothened agonist 
(SAG), cholesterol 
Following binding of the extracellular ligand, the receptor undergoes a characteristic 
conformational change, promoting a signalling cascade within the cell [9]. This movement 
is proposed to include a series of molecular switching and repacking of key contacts 
within the intra- and interhelical arrangement, followed by the outward movement of 
TMs 5 and 6 away from the TM bundle [10]. TM6 is then thought to undergo a mechanical 
rotation at the intracellular face, allowing exposure of a binding cleft which enables re-
cruitment of the G protein, and subsequent propagation of the signalling cascade. Move-
ment is therefore thought to be focussed around the intracellular end of TM6 and more 
recently, TM7 has also been observed to move towards TM3 [11]; overall, the molecular 
activation of GPCRs remains complicated to elucidate exactly. As shown in Figure 1b, 
heterotrimeric G proteins are composed of three subunits (α, β and γ); the α subunit facil-
itates an exchange of GDP for GTP, while the βγ complex splits away to signal inde-
pendently from Gα [9]. As humans encode 18, 5 and 12 different α, β and γ subunits re-
spectively, these combine into a variety of stimulatory or inhibitory effects on the subse-
quent signalling pathways. These intracellular signals often result in changes to protein 
activity or transcription factors, affecting cell behaviour (second messenger signaling, for 
example) depending on the combination of ligand and receptor in question [9]. Neverthe-
less, the exact molecular determinants underlying GPCR-G protein coupling also remain 
to be fully elucidated. 
Overall, the relationship between structure and function of GPCRs is of utmost im-
portance as the tertiary structure of the receptor contributes to determining the orthosteric 
and allosteric ligand binding domains, the efficiency of the conformational change and 
the receptors’ interaction with other proteins and lipids as well [12]. It would therefore 
seem logical to conclude that intended or unintended modifications of a GPCRs wildtype 
sequence/structure may impact on its efficacy as a functional membrane protein. Despite 
this, researchers frequently perform such modifications including thermostabilising mu-
tations and chimeric fusions because of the need for enhanced stability during expression 
and purification, for example [13–16]. 
We therefore hypothesised that resolved structures would not only show differences 
between conformational states, but that any modifications may also show a difference 
when compared to the unmodified structure. Any significant differences may therefore 
correlate with constraining the receptor to a certain conformation, of which the researcher 
should be aware. However, equally, no differences observed may indicate that the partic-
ular modification is ‘safe’ to use, and the GPCR structure is not significantly impacted 
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upon. To study these potential differences between resolved GPCR structures, the design 
rationale highlighted the importance of an objective and robust system of collecting data, 
with unbiased and mathematical analyses. 
Geometric morphometrics was selected for this task as it can quantify variation be-
tween shapes and fulfils the criteria of the design rationale; when the data is transformed, 
a morphospace is produced where objects are positioned based upon differences or simi-
larities in shape [17–19]. Geometric morphometrics can therefore quantifiably capture and 
display these shape variations between resolved GPCR structures, in a three-dimensional 
format. The data required for this method are Cartesian landmark coordinates and should 
be common reference points between the shapes [18]. As such, the seven transmembrane 
helices of GPCRs can be used as they are the defining structural characteristic of these 
receptors and remain relatively conserved between receptors. In order to assess any shape 
variation at the extra- and intracellular face of the receptor, both ends of the TM helices 
were selected as reference points; each receptor, by definition, contains these landmarks. 
More specifically, the XYZ coordinates of the alpha-carbon atom (Cα) of the amino acid 
residue at each end of the helix (meaning the first and last residue of each TM helix) were 
selected as the Cartesian landmarks to minimize variation due to amino acid identity at 
these positions. 
A comprehensive explanation of geometric morphometrics can be found elsewhere 
[17,18,20]; however, the main elements are as follows. The landmark coordinates are first 
size- and rotation-adjusted by a Procrustese superimposition; this is an orthogonal trans-
formation to standardise and scale the data for comparison [21]. Subsequently, a covari-
ance matrix is generated from which principal component analysis is then performed. 
Principal components are a series of vectors which show variation in the data and are 
composed of the eigenvectors of the data’s covariance matrix. An eigenvector is a direc-
tion with variation, and its eigenvalue is the variance of that direction [22]. As such, the 
principal components of the data produce a morphospace where the first principal com-
ponent is responsible for the greatest variation between the coordinate data [23]. As prin-
cipal component analysis uses covariance, its analysis is two-dimensional and therefore 
principal component scores can be compared; a comparison between principle compo-
nents 1 and 2 (PC1 and PC2) will show the greatest variation in the morphospace. Overall, 
geometric morphometrics with principal component analysis breaks down three-dimen-
sional landmark coordinates to find patterns in the data, because of their shape variations, 
and can be further analysed statistically by analysis of similarity (ANOSIM) and permu-
tational multivariate analysis of variance (PERMANOVA) [17,23]. 
We therefore present an application of geometric morphometric analysis to resolved 
GPCR structures which is, to our knowledge, the first demonstration of its suitability for 
membrane protein analysis. Overall, we have been able to classify, discriminate and math-
ematically determine significant differences between GPCR structures based on their 
characteristics such as activation state, bound ligands and fusion proteins. While this is a 
method more often used in disciplines such as anthropology and palaeontology, we be-
lieve that this technique has wide applicability to the structural biology field. By increas-
ing understanding of GPCR structures resolved under varied conditions, it is hoped that 
intelligent, structure-based ligand design will continue to improve and expand the current 
range of druggable receptors. 
2. Results 
2.1. From XYZ Coordinates to Principal Component Analysis 
Before detailing some examples of the receptor group analyses, the steps leading to 
the final principal component analysis should be highlighted first for context. This should 
also familiarise the reader with the various figures produced by the MorphoJ software 
[24]. The extracellular face of the β2-adrenergic receptors (β2AR) is shown as the example 
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in Figure 2, though each subsequent analysis presented always entailed the following pro-
cess. 
Initially, after importing the appropriate XYZ coordinate data from PDB files into the 
MorphoJ software, a generalised Procrustese transformation was performed with align-
ment to the principal axes. To effectively compare the shape variation, the data must first 
be standardised. The Procrustese transformation does this by translation, rotation, scaling 
and superimposition of the coordinate data (Figure 2a). The blue numbered circles are the 
average of the positions included in the dataset (in this case, of the extracellular face of the 
β2AR TM helix bundle), and the smaller black dots around them are each individual struc-
ture’s position. Once the selected dataset had been standardised, a covariance matrix was 
generated; this measures how much shapes vary together and allows for statistical anal-





Figure 2. The four graphs generated by geometric morphometrics and principal component analysis using extracellular 
β2AR data as an example. (a) Generalised Procrustese transformation standardises the dataset to show an average position 
(blue numbered dots) and the individual data (black dots) around them. In this case, this can be thought of as a top-down 
view of the extracellular TM bundle. (b) Lollipop graph visualising morphospace variation caused by principle component 
1 (PC1). The average position of each helix is represented by the blue dot; the stick protruding away from the dot shows 
the direction and magnitude of variation caused by PC1 (the greatest source of variation). (c) Principal component eigen-
values and the percentage of variance they account for—PC1 always gives the most variance, and then PC2 second, and 
so on. (d) Comparison between PC1 and PC2; this is used to assess the greatest variation of the dataset’s morphospace 
and to observe patterns produced by the data. Each dot represents a GPCR structure within the selected dataset and can 
be labelled with PDB codes or different colours. A list of structures included in each figure can be found in the Appendix 
A tables, and further supplementary figures in Appendix B. 
Firstly, the principal component (PC) scores are calculated through eigendecomposi-
tion of the covariance matrix values and projection of shape variables onto low-
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dimensional space (a 2D graph, for example). Figure 2b shows the overall direction and 
magnitude of the greatest variation caused by PC1 of this dataset; to interpret the lollipop 
graph, the blue circle is the average position of each helix, while the protruding stick rep-
resents its overall movement. Figure 2b therefore displays an equal movement of TM6 
away from the helix bundle, and TM1 towards TM2; conversely, for this dataset, TMs 2, 5 
and 7 move very little in comparison. 
Principal components are directional vectors which maximise data variation and are 
ranked by the percentage variation they cause, based on the dataset’s eigenvectors and 
eigenvalues (Figure 2c). PC1 will always represent the greatest variation, with PC2 the 
second most, and so on. As shown in Figure 2c, the first two principal components com-
bined account for more than 70% of the shape variations in the structures in this dataset. 
The greatest comparison of variation can therefore be observed by comparing PC1 and 
PC2 (Figure 2d). At this point, if two receptor structures were identical, they would oc-
cupy the same space on this graph. However, there are clear differences between the struc-
tures in this dataset and correlation with characteristics need to be inferred manually. This 
is because principle component analysis can show variation between shapes in an unbi-
ased manner but cannot explain or interpret the data. From here on, examples of receptor 
group analyses will be shown comparing both the extra- and intracellular data (left and 
right, respectively). The comparisons between PC1 and PC2 will be shown in text, along 
with the results of the statistical tests; further relevant figures can also be found in the 
indicated appendices. 
2.2. Activation State—The β2-Adrenergic Receptors 
GPCR activation largely relies upon ligand binding, and so this was the first analysis 
performed; additionally, the active, intermediate and inactive states are well characterised 
within the available structures, providing a proof of concept for geometric morphometrics 
in this context. As summarised earlier, receptor activation entails movement of the TM 
bundle, and rotation of TM6 to enable recruitment of G proteins and other accessory pro-
teins to the intracellular face [10]. It was therefore hypothesised that GPCR structures cap-
tured in different activation states would show variation between each other, particularly 
at the intracellular face where movement is focussed. The β2-adrenergic receptors (β2AR) 
were selected to highlight this example, not only because it is a widely studied GPCR, but 
this group had ample numbers to analyse, and a mixture of activation states based on the 
hypothesis. Of the 36 β2AR structures studied, 23 were described as inactive, 7 as active 
and 6 as active bound to Gs. A list of the PDBs is provided in Appendix A Table A1. Inac-
tive structure 5JQH was not included in analyses due to heavily skewing the data [25]; we 
hypothsise that it is possibly due to it being allosterically nanobody stabilised. 
Once the PC scores were generated, colours were assigned to each activation state as 
defined by the GPCRdb database [26], where inactive is red, active is blue and active with 
Gs coupled is green (Figure 3). The β2AR extracellular face data in Figure 3a shows both 
active and inactive categories generally occupying the same morphospace suggesting that 
when these receptors were captured in their states, the extracellular face of the TM helices 
do not discriminate between inactive and active. ANOSIM and PERMANOVA were then 
carried out on the principal component scores to test for the significance of clusters and 
distance. These gave relatively low R and F values overall (0.2965 and 4.142, p = 0.0047 
and p = 0.0003), indicating the extracellular data are reasonably similar but vary somewhat 
from each other (Tables 2 and 3). 
However, the β2AR intracellular face shows significant differences between recep-
tors in different groups. As shown in Figure 3b, not only are there visible variations be-
tween structures, the active and inactive groups separate entirely. This also occurs with 
alignment to the PC1 axis which could therefore describe β2AR activation; a negative PC1 
score correlates with inactive structures (red), while a positive score correlates with active 
(blue and green). The intracellular ANOSIM and PERMANOVA data also gave relatively 
higher R and F values (0.8967 and 16.17, p = 0.0001 and p = 0.0001) which is indicative of 
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dissimilarity between groups (Tables 2 and 3). Interestingly, while overlapping with the 
inactive group (red), the active (blue) and active coupled to Gs (green) groups were seen 
to be distinct at the extracellular face, but not intracellularly. 
These analyses have therefore clearly demonstrated a difference between the active 
and inactive β2AR structures at the intracellular face of the transmembrane helix bundle, 
as hypothesised. These results were also supported by the significance of the statistical 
tests and provide proof of concept that the application of geometric morphometrics with 
principal component analysis to GPCRs was successful and could also be applied to fur-
ther receptor characteristics as well. 
  
(a) (b) 
Figure 3. Principal component analysis to show the β2-adrenergic receptor (β2AR) shape variation between activation 
states. Inactive structures are red, active are blue and active with Gs coupled are green. (a) PC score comparison for the 
extracellular face of the β2AR transmembrane bundle. (b) PC score comparison for the intracellular face of the β2AR 
transmembrane bundle. The supporting statistical data are summarised in Tables 2 and 3. Additional supporting figures 
are found in Appendix B Figure A1. 
Table 2. A summary of ANOSIM (clustering) test data for the extra- and intracellular faces of the β2AR receptors, to 
support Figure 3; 9999 permutations performed on PC1-5, significant p values (<0.05) are shown in bold. 
Extracellular Intracellular 
ANOSIM ANOSIM 
R value 0.2965 R value 0.8967 
p value 0.0047 p value 0.0001 
Pairwise p Values Pairwise p Values 
 Inactive Active Gs  Inactive Active Gs 
Inactive  0.0026 0.1273 Inactive  0.0001 0.0001 
Active 0.0026  0.0073 Active 0.0001  0.0062 
Gs 0.1273 0.0073  Gs 0.0001 0.0062  
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Table 3. A summary of PERMANOVA (distance) test data for the extra- and intracellular faces of the β2AR receptors, to 
support Figure 3; 9999 permutations performed on PC1-5, significant p values (<0.05) are shown in bold. 
Extracellular Intracellular 
PERMANOVA PERMANOVA 
F value 4.142 F value 16.17 
p value 0.0003 p value 0.0001 
Pairwise p Values Pairwise p Values 
 Inactive Active Gs  Inactive Active Gs 
Inactive  0.0005 0.1354 Inactive  0.0001 0.0001 
Active 0.0005  0.0166 Active 0.0001  0.0753 
Gs 0.1354 0.0166  Gs 0.0001 0.0753  
2.3. Bound Ligands—The Family B Receptors 
Whilst differences were observed with receptor activation state, these are often 
caused by the ligands bound to them. Just as there are a wide variety of GPCRs, their 
ligands are just as diverse, including light, ions, small molecules, peptides and proteins; 
each of these can be categorised by the effect they exert on the receptors and its pharma-
cology. These include agonist, partial agonist, biased agonist, antagonist, inverse agonist 
and positive and negative allosteric modulators (PAM and NAM) [6]. It was therefore 
hypothesised that variation would be observed in GPCR structures with these different 
categories of ligand bound to them. The family B receptor group was selected due to am-
ple numbers and a mixture of ligand-bound structures. Of the 54 family B structures stud-
ied, 38 were described as agonist-bound, one partial agonist-bound, six antagonist-bound, 
five as negative allosteric modulator-bound and three in an unbound state. A list of the 
PDBs is provided in Appendix A Table A2. Structure 6FJ3 was not included in analyses 
due to unusable annotation and 6ORV was not included due to PDB unavailability. 
After PC scoring, agonist-bound structures were labelled red, partial agonist blue, 
antagonist yellow, NAM green and unbound purple (Figure 4). In a similar way to the 
activation states of the β2-adrenergic receptors, the extracellular face of the family B struc-
tures showed variation, with agonist bound structures largely in the negative distribution 
of data; however, again, there was a general overlap and no clear clustering (Figure 4a). 
ANOSIM and PERMANOVA gave low R and F values (0.01442 and 3.02, p = 0.4207 and p 
= 0.0024) which indicates similarity between these groups (Tables 4 and 5). This makes 
sense biologically as the family B receptors often share affinity to several of their peptide 
hormone ligands, albeit to a varying extent. 
However, again, there were more visible differences at the intracellular face of family 
B (Figure 4b). Similarly, the ligand categories aligned to the PC1 axis showing a gradient 
of active to inactive effects from negative to positive. Agonist-bound structures (red) cor-
related with a negative PC1 score and less active or inactive structures gave a positive 
score. Unbound structures fell somewhere between the extremes of agonist and antago-
nist/NAM. ANOSIM and PERMANOVA R and F values were relatively higher for the 
intracellular face (0.7606 and 13.94, p = 0.0001 and p = 0.0001) indicative of dissimilarity 
between these ligand groups (Tables 4 and 5). 
These results therefore show shape variation between ligand-bound receptors within 
family B, at the intracellular face, again supported by the statistical data. These data per-
haps show less clear separation between bound ligand types due to family B being larger, 
and containing several sub-groups within it, when compared to the β2AR group. Further-
more, many of the family B receptors often co-express with an accessory protein needed 
for trafficking or full activation [27]; a lack of which may hinder their true structural dy-
namics. Nevertheless, there are clear groupings, demonstrating the applicability of geo-
metric morphometric analysis in different scenarios. 





Figure 4. Principal component analysis to show the family B receptor shape variation due to bound ligands. Agonist-
bound structures are red, antagonist yellow, negative allosteric modulator (NAM) green, partial agonist blue and unbound 
purple. (a) PC score comparison for the extracellular face of the family B transmembrane bundle. (b) PC score comparison 
for the intracellular face of the family B transmembrane bundle. The supporting statistical data are summarised in Tables 
4 and 5. Additional supporting figures are found in Appendix B Figure A2. 
Table 4. A summary of ANOSIM (clustering) test data for the extra- and intracellular faces of the family B receptors, to 
support Figure 4. For statistical analysis, the partial agonist structure (5YQZ) was included in the agonist group; 9999 
permutations performed on PC1-5, significant p values (<0.05) are shown in bold. 
Extracellular Intracellular 
ANOSIM ANOSIM 
R value 0.01442 R value 0.7606 
p value 0.4207 p value 0.0001 
Pairwise p Values Pairwise p Values 
 Agonist Antagonist NAM Unbound  Agonist Antagonist NAM Unbound 
Agonist  0.4181 0.1937 0.5556 Agonist  0.0001 0.0001 0.0132 
Antagonist 0.4181  0.1211 0.2648 Antagonist 0.0001  0.3958 0.2146 
NAM 0.1937 0.1211  0.3855 NAM 0.0001 0.3958  0.0352 
Unbound 0.5556 0.2648 0.3855  Unbound 0.0132 0.2146 0.0352  
Table 5. A summary of PERMANOVA (distance) test data for the extra- and intracellular faces of the family B receptors, 
to support Figure 4. For statistical analysis, the partial agonist structure (5YQZ) was included in the agonist group; 9999 
permutations performed on PC1-5, significant p values (<0.05) are shown in bold. 
Extracellular Intracellular 
PERMANOVA PERMANOVA 
F value 3.02 F value 13.94 
p value 0.0024 p value 0.0001 
Pairwise p Values Pairwise p Values 
 Agonist Antagonist NAM Unbound  Agonist Antagonist NAM Unbound 
Agonist  0.0054 0.0059 0.3527 Agonist  0.0001 0.0001 0.0105 
Antagonist 0.0054  0.0246 0.7125 Antagonist 0.0001  0.3886 0.1684 
NAM 0.0059 0.0246  0.1635 NAM 0.0001 0.3886  0.0171 
Unbound 0.3527 0.7125 0.1635  Unbound 0.0105 0.1684 0.0171  
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2.4. Fusion Proteins—The Orexin Receptors 
Fusion proteins can be incorporated into the target receptor for a variety of reasons 
including greater stability during expression, a cleavable target during purification and 
enhanced identification during crystallisation. Glycogen synthase is one such fusion pro-
tein, in this case replacing part of ICL3 of the orexin receptors. This was engineered to 
enhance crystallisation during the vapor diffusion and lipidic cubic phase methods of X-
ray diffraction [28]. Note that each of these receptors had first undergone a series of 12 
thermostabilising mutations to create the StaR (stabilised receptor) proteins [29], as well 
as the fusion. It was hypothesised that adding a 196 amino acid insertion into ICL3 may 
have an impact on the orexin receptor structures, undetectable through pharmacology. It 
must be remembered that crystallography provides a ‘snapshot’ structure and, although 
proteins may function in cells where they are dynamic, their determined structures could 
be biased towards particular conformations by the introduction of such fusions; this is an 
important consideration in the field. Indeed, to our knowledge, these structures have not 
been compared previously and geometric morphometric analysis will enable quantifica-
tion of any differences due to fusions. Of the 22 orexin receptors studied, nine contained 
the fusion protein and 13 did not. A list of the PDBs is provided in Appendix A Table A3. 
Following PC scoring, glycogen synthase fusions were labelled red, and no fusion 
labelled as blue (Figure 5). The extracellular face data showed the receptors with fusion 
proteins clustered in the bottom-right space of the graph with some overlap of the non-
fusion group (Figure 5a). ANOSIM and PERMANOVA was performed, resulting in low 
R and F values (0.1018 and 4.33, p = 0.0879 and p = 0.0152) indicating similarity between 
groups (Tables 6 and 7). 
The intracellular face was observed to largely separate the two groups aligned to the 
PC1 axis (Figure 5b). Glycogen synthase fusion correlated with the positive PC score, with 
non-fusion as the negative. ANOSIM and PERMANOVA R and F values were higher than 
the extracellular data (0.6271 and 16.73, p = 0.0001 and p = 0.0002) indicating more dissim-
ilarity at the intracellular face (Tables 6 and 7). PC1, representing the largest variation in 
structure, could therefore correlate with the structural alterations caused by inserting gly-
cogen synthase into ICL3. Note that the variation was much clearer at the intracellular 
face which was the location of the fusion protein. 
There was one anomalous result observed where an orexin fusion (red) was found 
with the non-fusion group (blue) in the intracellular data. Nonetheless, we believe this is 
the first demonstration of geometric morphometrics in being able to significantly classify 
GPCR structures based upon the presence or absence of a glycogen synthase fusion pro-
tein. 
  





Figure 5. Principal component analysis to show the orexin receptor shape variation with a glycogen synthase fusion pro-
tein or not. Those with a glycogen synthase fusion are indicated in red, and those with no fusion are blue. (a) PC score 
comparison for the extracellular face of the orexin receptors transmembrane bundle. (b) PC score comparison for the in-
tracellular face of the orexin receptors transmembrane bundle. The supporting statistical data are summarised in Tables 6 
and 7. Additional supporting figures are found in Appendix B Figure A3. 
Table 6. A summary of ANOSIM (clustering) test data for the extra- and intracellular faces of the orexin receptors, to 
support Figure 5; 9999 permutations performed on PC1-5, significant p values (<0.05) are shown in bold. 
Extracellular Intracellular 
ANOSIM ANOSIM 
R value 0.1018 R value 0.6271 
p value 0.0879 p value 0.0001 
Pairwise p Values Pairwise p Values 
 Glycogen synthase No fusion  Glycogen synthase No fusion 
Glycogen synthase  0.0825 Glycogen synthase  0.0001 
No fusion 0.0825  No fusion 0.0001  
Table 7. A summary of PERMANOVA (distance) test data for the extra- and intracellular faces of the orexin receptors, to 
support Figure 5; 9999 permutations performed on PC1-5, significant p values (<0.05) are shown in bold. 
Extracellular Intracellular 
PERMANOVA PERMANOVA 
F value 4.33 F value 16.73 
p value 0.0152 p value 0.0002 
Pairwise p Values Pairwise p Values 
 Glycogen synthase No fusion  Glycogen synthase No fusion 
Glycogen synthase  0.0134 Glycogen synthase  0.0001 
No fusion 0.0134  No fusion 0.0001  
2.5. Thermostabilised Receptors 
During the expression, purification and experimentation of proteins, it is common 
practice to keep samples on ice as much as possible to prevent degradation of the sample’s 
quality or structural integrity [16]. This can be especially challenging with regards to tech-
niques used for solving GPCR structures and so the introduction of mutations can im-
prove the receptor’s stability at higher temperatures [30]. This is often achieved by 
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systematic mutagenesis which ultimately increases the protein’s rigidity, decreases over-
all mobility and gives more stable enthalpy stemming from improved interhelical packing 
when compared to wildtype [30]. These mutations have been shown to cause no pharma-
cological differences in some cases, but can in others; for example, some mutations in the 
neurotensin 1 receptors (NTS1R) cause them to no longer signal at all [31]. It is therefore 
important to understand whether these mutations cause significant structural changes or 
not, and whether they are ‘safe’ to use when determining GPCR structures. Several exam-
ples of receptor families were selected as they are well studied and include ample num-
bers of thermostabilised structures to compare against the non-mutated receptors. This 
group included the adenosine A2a receptors (A2AR), the β1-adrenergic receptors (β1AR) 
and the β2-adrenergic receptors (β2AR). In total, these groups included 60 thermostabi-
lised structures and 64 non-mutated. A list of the PDBs is provided in Appendix A Tables 
A1, A4 and A5. 
After PC scoring, thermostabilised structures were labelled red, and non-mutated as 
blue (Figure 6). Overall, the data analysed showed no significant differences between the 
thermostabilised and non-mutated receptors, at both the extra- and intracellular faces of 
the TM bundle. When analysing this larger groups of receptors, extracellular ANOSIM 
and PERMANOVA tests gave low R and F values (0.07405 and 5.442, p = 0.0003 and p = 
0.0024) indicating similarity between groups (Tables 8 and 9). Similarly, the intracellular 
R and F values were also low (0.02588 and 2.854, p = 0.0452 and p = 0.0525), indicative of 
similarity as well (Tables 8 and 9). This observation was also consistent with other anal-
yses performed (data not shown). When the thermostabilised data in Figure 6 were sepa-
rated between the A2AR, β1AR and β2AR receptors, or including other GPCRs (such as 
the neurotensin and substance P receptors), results were consistent, and no significant 
differences were observed in any analysis. 
These results suggest that, in terms of the receptors analysed, thermostabilising mu-
tations did not cause any significant variation from the non-mutated receptors. This sup-
ports the idea of utilising thermostabilising mutations to enhance the experimentation of 
GPCRs and, possibly, other important membrane proteins as well. This reassurance is 
particularly valuable as many medically relevant GPCRs can often undergo these muta-




Figure 6. Principal component analysis to show the shape variation between non-mutated and thermostabilised receptors. 
Non-mutated are blue and thermostabilised are red. (a) PC score comparison for the extracellular face of the A2AR, β1AR 
and β2AR transmembrane bundles. (b) PC score comparison for the intracellular face of the A2AR, β1AR and β2AR 
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transmembrane bundles. The supporting statistical data are summarised in Tables 8 and 9. Additional supporting figures 
are found in Appendix B Figure A4. 
Table 8. A summary of ANOSIM (clustering) test data for the extra- and intracellular faces of the A2AR, β1AR and β2AR 
receptors, to support Figure 6; 9999 permutations performed on PC1-5, significant p values (<0.05) are shown in bold. 
Extracellular Intracellular 
ANOSIM ANOSIM 
R value 0.07405 R value 0.02588 
p value 0.0003 p value 0.0452 
Pairwise p Values Pairwise p Values 
 Thermostabilised Non-mutated  Thermostabilised Non-mutated 
Thermostabilised  0.001 Thermostabilised  0.0456 
Non-mutated 0.001  Non-mutated 0.0456  
Table 9. A summary of PERMANOVA (distances) test data for the extra- and intracellular faces of the A2AR, β1AR and 




F value 5.442 F value 2.854 
p value 0.0024 p value 0.0525 
Pairwise p Values Pairwise p Values 
 Thermostabilised Non-mutated  Thermostabilised Non-mutated 
Thermostabilised  0.0018 Thermostabilised  0.0564 
Non-mutated 0.0018  Non-mutated 0.0564  
3. Discussion 
GPCRs are widely studied membrane protein receptors due to their involvement in 
disease states, and potential as drug targets. Despite their importance, development of 
novel, specific and effective prophylaxis can often be hindered by a lack of structural 
knowledge and understanding of these dynamic receptors. Thus, the application of inno-
vative techniques to this field will undoubtedly further enhance understanding of GPCR 
structures and modifications, to ultimately improve their druggability. We hypothesised 
that differences between GPCR structures, under varying conditions, could be detected, 
quantified and analysed statistically using geometric morphometrics. This mathematical 
technique was therefore used with principal component analysis to assess receptor shape 
variation in a three-dimensional, unbiased manner. The results obtained demonstrated 
that this technique was successfully applied to GPCR structures and gave insight into the 
modifications researchers frequently perform with them. 
As geometric morphometrics is mainly utilised in disciplines such as anthropology 
and palaeontology, it was first necessary to understand if it could be applied to protein 
structures as well. One unpublished example exists on the bioRxiv database which exam-
ines the soluble α-amylase enzymes with geometric morphometrics [32]. However, after 
an initial pilot study and further expansion of our methods, we believe this is the first 
application of this technique to GPCRs, and membrane proteins in general, especially on 
this scale. 
We first demonstrated that the XYZ coordinates of amino acids are not only compat-
ible with the MorphoJ software, but produce figures which make sense. The generalised 
Procrustese transformations presented (e.g., Figure 2a) show the average helical positions 
which, when compared back to GPCR structures, accurately represent a view of the trans-
membrane helix bundle at both the extra- and intracellular faces. This meant that the co-
ordinate data was transformed into a standardised and reliable dataset from which the 
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subsequent analyses could be performed with confidence. Similarly, the overall direction 
and magnitude of the dataset’s variation was able to be portrayed by the lollipop graphs 
(e.g., Figure 2b), indicating which helices vary the most under different conditions. Fi-
nally, the principal component score comparisons (e.g., Figure 2d) provided an unbiased 
platform to then infer meaning by grouping receptors together and statistically analysing 
the dissimilarity between those groups. 
Initially, receptor activation was selected as the characteristic to provide proof of con-
cept as it is the main source of natural variation between structures. It is a movement 
native to all wild-type GPCRs, and is reasonably well understood [33]. Based on the gen-
erally accepted model of activation, it was hypothesised that GPCRs resolved in different 
activation states should vary from one another. Helical movement would therefore be ex-
pected, with a focus on the intracellular face of the transmembrane bundle. Reassuringly, 
these predictions were proved to be correct as shown in Appendix B Figure A1b,e. TM6 
was highlighted as the main location of variation between activation states, moving away 
from the TM bundle as expected. Subsequently, comparison of the intracellular principal 
component scores (Figure 3b) showed very clear separation between activation states. The 
group of inactive β2AR receptors were observed to significantly differ from the active or 
active with Gs groups, and thus further confirm our hypothetical predictions. These re-
sults are therefore likely indicative of the conformational movement to allow post-activa-
tion binding of the intracellular G protein and propagation of the appropriate signalling 
pathway, as predicted. Additionally, the significant separation of the active and active 
coupled to Gs groups at the extracellular face should also be noted (Figure 3a). This unex-
pected result suggests that the binding of a stimulatory G protein possibly causes bias to 
the extracellular face of the β2AR TM bundle to adopt a different conformation than those 
with only agonist bound to them. Interestingly, this was not observed at the intracellular 
face despite being the location of G protein binding, providing a thought-provoking ave-
nue for further research. Indeed, it has been observed that binding of a G protein to a 
GPCR can increase the affinity for ligands, which may be as a result of changes to the 
extracellular face [34]. Nevertheless, these convincing results provide strong evidence to 
support the use of geometric morphometrics with GPCRs and that it can be further ap-
plied to highlight structural variation under additional conditions. 
As receptor activation largely relies upon ligand binding, this was the next charac-
teristic studied. This is especially interesting as GPCRs can interact with a variety of dif-
ferent ligand types, and with bias towards certain ligands or signalling pathways. One 
explanation may involve a specific helical movement which opens an intracellular binding 
cleft biased towards certain G proteins, either stimulatory or inhibitory, etc. We therefore 
hypothesised that GPCR structures with different ligand classes bound to them may vary 
from each other, again, possibly focussed at the intracellular face. The extracellular data 
of the family B receptors showed a general similarity with no significantly different group-
ings (Figure 4a). This possibly suggests that as the N terminus of their peptide hormone 
ligands bind to a residue close to the TM bundle and ECL2, the extracellular face of the 
TM bundle arrangement remains more similar across the family B receptors, perhaps due 
to their shared ligand affinity [35]. However, the intracellular face exhibited significant 
variation (Figure 4b), with agonist bound structures shown to be most dissimilar to the 
structures resolved with antagonist or NAM bound to them, and unbound structures fall-
ing somewhere between the two. One possible explanation for this may include a greater 
involvement of the intracellular helix arrangement in the bias towards certain G protein 
pathways, as a result of ligand binding. It is also interesting to observe that the structural 
variation of the partial agonist-bound receptor (blue) was more similar to antagonist-
bound rather than agonist-bound. Looking in more depth at this PDB file (5YQZ), it is 
nonetheless described as inactive which could explain this observation [36]. Furthermore, 
several of these family B receptors can require co-expression with an accessory protein 
called a receptor activity modifying protein (RAMP) [27]. Biologically, these RAMPs can 
influence trafficking to the cell membrane, glycosylation and receptor pharmacology. 
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Crystallisation without a RAMP, in some cases, could therefore hinder a family B GPCR’s 
full dynamic range, and should be considered when studying their resolved structures. 
Nonetheless, these results demonstrate the ability of geometric morphometrics to signifi-
cantly discriminate structures based upon their bound ligands, with a meaningful gradi-
ent of activation across the principal component score axis. 
While the analysis of activity and bound ligands supported our hypotheses based on 
existing GPCR understanding, we also focussed our attention to modifications frequently 
performed during the experimentation of proteins. These included the insertion of an in-
tracellular fusion protein and the introduction of receptor thermostabilising mutations, 
highlighting some important results to share. 
Firstly, insertion of a glycogen synthase fusion protein into the ICL3 of the orexin 
receptors caused significant variation at the intracellular face (Figure 5b). Despite seem-
ingly having no effect on their pharmacology, the presence of the fusion protein appears 
to largely bias these receptors to a significantly different intracellular conformation. This 
is important for the field to be aware of during experimental design as intracellular fusion 
proteins could sterically hinder the receptor’s full range of motion or bias structures to 
more stable conformations that do not necessarily fully represent the in vivo state of the 
protein. One anomalous result was found to have the opposite effect where the insertion 
of a fusion protein caused no difference from those without the fusion. It is interesting 
that this structure (6V9S) was bound with a novel antagonist (JH112) made by enantiospe-
cific synthesis [37], whereas the other structures had their typical non-selective antagonist 
Suvorexant bound to them. JH112 is a sub-nanomolar antagonist to activate Gq mediated 
recruitment of β-arrestin to the orexin 1 receptors [37], and further study is likely required 
to confirm whether JH112 can bias the orexin receptor to a different intracellular confor-
mation than the other antagonist-bound structures. In any case, we believe this is the first 
demonstration of using geometric morphometrics to indicate that an intracellular fusion 
modification can cause significant variation at the intracellular face of GPCRs. 
Finally, thermostabilising mutations remain to be a more controversial area of GPCR 
research as conflicting opinions on its use still persist. Some groups advocate for the ad-
vantages thermostability provides experimentally, especially when resolving difficult 
structures [38]. However, others promote a degree of caution when using non-native pro-
teins and emphasise the need to ensure proteins are active. Either way, thermostabilising 
mutations remain a prevalent component of the holistic approach to studying protein 
structures. Ultimately, our analyses did not detect any significant differences between 
thermostabilised and non-mutated GPCRs, from a variety of receptor sub-groups (Figure 
6); this perhaps suggests that, on a geometric level, thermostabilising mutations are “safe” 
to use. However, given that some receptors are no longer able to signal after this modifi-
cation, it would be pragmatic to comprehensively analyse one’s GPCR of interest, none-
theless. 
One downside to this method is its manual nature; the variety of annotated PDB files 
makes automation difficult to attempt though this may become possible in the future. De-
spite this, geometric morphometrics is an overwhelmingly advantageous technique. 
Landmark coordinates are not restricted to the ends of the transmembrane helices, other 
locations such as the middle of helices could be analysed, and they must simply be com-
mon to each structure. Similarly, this technique is not limited to GPCRs and could be ap-
plied to other proteins of interest such as ABC transporters and aquaporins [39,40]. While 
interesting results and structural differences were observed with regards to the character-
istics presented in this paper, we have also been able to classify receptors based on further 
factors including organism species, highlighting possible future analyses. With regards to 
GPCRs, an area requiring further study is the explanation of G protein coupling specificity 
[41], especially concerning intermediate states and the role of the intracellular binding 
cleft. Another exciting possibility involves checking the validity of the recent AlphaFold 
project predictions—at the time of writing, these predicted structures seem reasonable 
although limited to inactive states for now [42,43]. To conclude, the results presented in 
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this paper provide a proof of concept for the use of geometric morphometrics in the study 
of GPCR structures, especially when variation may be undetectable by pharmacological 
assays or other structural techniques such as root-mean-square deviation (RMSD). We 
have therefore adapted a method to apply this mathematical technique and demonstrate 
meaningful and statistically significant analyses. It is ultimately intended to be a tool to 
aid sense-checking newly resolved structures and planning early experimental design, 
even beyond GPCRs. 
4. Materials and Methods 
A database of all currently known GPCR structures was first obtained from the 
GPCRdb website (https://gpcrdb.org/structure/ (accessed on 21 August 2021)) and cross-
referenced to the mpstruc database (https://blanco.biomol.uci.edu/mpstruc/ (accessed on 
21 August 2021)) to ensure the working model was based upon a comprehensive list of 
resolved structures (last sampled 30 June 2021) [26,44]. From here, the PDB code of each 
structure was used to download the .pdb file from the Research Collaboratory for Struc-
tural Bioinformatics Protein Data Bank (https://www.rcsb.org/ (accessed on 21 August 
2021)). Next, the Swiss-PdbViewer (DeepView) software version 4.10 
(http://www.expasy.org/spdbv/ (accessed on 21 August 2021)) was used to visualise and 
manipulate the structures before data collection [8]. Finally, data processing and statistical 
analysis was performed with the MorphoJ software (https://morphometrics.uk/Mor-
phoJ_page.html (accessed on 21 August 2021)) and the PAST data analyser software 
(https://past.en.lo4d.com/windows (accessed on 21 August 2021)) [24,45]. All of these are 
freely available. 
Each receptor structure was analysed using the same process as follows. Firstly, the 
amino acid residues located at the very end of each transmembrane helix were identified 
manually and the name and sequence number recorded. As GPCRs have seven transmem-
brane helices, this results in fourteen landmarks for each structure: Seven at the extracel-
lular face, and seven at the intracellular face. Next, the .pdb file was opened as text and 
the x, y and z coordinates located and recorded for each of the fourteen identified residues. 
Specifically, these were the coordinates for the alpha-carbon atom (Cα) for each residue. 
These were then divided into two groups (extra- and intracellular) and then exported as 
.txt files. This manual process was repeated exactly for every structure analysed. We en-
visage that this process could be automated, although the disparity between presentation 
and annotation of the .pdb files could well hinder attempts. 
A new project was then started in MorphoJ, with the relevant .txt file imported as 
three-dimensional data (the extracellular data was processed separately to the intracellu-
lar). Two preliminary processes were then performed. Firstly, a Procrustese fit was per-
formed with the data aligned by principal axes, and then a covariance matrix was gener-
ated. Finally, principal component analysis was performed which gives the principal com-
ponent shape changes, eigenvalues and scores [24]. The PC score comparisons were then 
used to identify groups, clusters and outliers based upon the characteristics of the GPCR 
structure. Any overlap or differences in data have been highlighted by the addition of 
coloured convex hulls to the PC comparisons which demarcate the smallest area contain-
ing each group. 
These PC scores were then tested statistically using PAST [45]; one-way permuta-
tional multivariate analysis of variance (PERMANOVA) tested the distance between the 
centroids of each group, while one-way analysis of similarity (ANOSIM) tested group dis-
similarity. Both of these multivariate tests involved 9999 permutations and pairwise com-
parisons were performed using Euclidean distances. PERMANOVA gives P and F values, 
testing for differences between groups by distance; a larger F value indicates a more pro-
nounced group separation. ANOSIM gives P and R values, using the mean rank of dis-
tances between and within groups; an R value of 1 indicates complete dissimilarity. Sig-
nificance for both tests is calculated by 10,000 permutations of group membership [17]. 
  




Historically, GPCR structures have been typically difficult to study, owing to their 
complex, dynamic structures, and the limitations of membrane protein production at the 
time. As these processes have developed and improved over the last few decades, so have 
the quantity and quality of resolved GPCR structures; as of September 2021, there are over 
one thousand GPCR structure models available, with nearly two hundred thousand lig-
ands and thirty thousand ligand interactions discovered so far (GPCRdb). This puts the 
field in a position to discover potential treatments for the many conditions which still have 
limited or no options in terms of effective prophylaxis involving GPCRs. We have first 
demonstrated that the novel application of geometric morphometrics with principal com-
ponent analysis to GPCRs was successful as a proof of concept, and is able to discriminate 
between structures based on their characteristics. This method can therefore be used as a 
tool to further study the variation between structures, correlated with these characteristics 
including receptor activity, bound ligand classes, presence of fusion proteins etc. Notably, 
our results have thus far suggested that thermostabilising mutations do not cause signifi-
cant differences. Overall, we believe this is a beneficial, unbiased technique with wide 
applicability to the structural biology field and can form the basis for further development 
of geometric morphometrics with GPCRs. 
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Appendix A 
Table A1. A list of all β2-adrenergic receptor (β2AR) structures used in Figures 2, 3 and 6. Included are the PDB code, 
description, and resolution in Ångströms. Structure 5JQH was not included in analyses due to heavily skewing the data 
as it is nanobody stabilised. 
PDB 
Code 
Description Resolution, Å 
2R4R Crystal structure of the human beta2 adrenoceptor 3.4 
2R4S Crystal structure of the human beta2 adrenoceptor 3.4 
2RH1 High resolution crystal structure of human B2-adrenergic G protein-coupled receptor. 2.4 
3D4S Cholesterol bound form of human beta2 adrenergic receptor. 2.8 
3KJ6 Crystal structure of a Methylated beta2 Adrenergic Receptor-Fab complex 3.4 
3NY8 
Crystal structure of the human beta2 adrenergic receptor in complex with the inverse ago-
nist ICI 118,551 
2.8 








Crystal structure of the human beta2 adrenergic receptor in complex with the neutral an-
tagonist alprenolol 
3.2 
3P0G Structure of a nanobody-stabilized active state of the beta2 adrenoceptor 3.5 
3PDS Irreversible Agonist-Beta2 Adrenoceptor Complex 3.5 
3SN6 Crystal structure of the beta2 adrenergic receptor-Gs protein complex 3.2 
4GBR 
N-Terminal T4 Lysozyme Fusion Facilitates Crystallization of a G Protein Coupled Recep-
tor 
4 
4LDE Structure of beta2 adrenoceptor bound to BI167107 and an engineered nanobody 2.8 
4LDL 
Structure of beta2 adrenoceptor bound to hydroxybenzylisoproterenol and an engineered 
nanobody 
3.1 
4LDO Structure of beta2 adrenoceptor bound to adrenaline and an engineered nanobody 3.2 
4QKX Structure of beta2 adrenoceptor bound to a covalent agonist and an engineered nanobody 3.3 
5D5A 
In meso in situ serial X-ray crystallography structure of the Beta2-adrenergic receptor at 
100 K 
2.5 
5D5B In meso X-ray crystallography structure of the Beta2-adrenergic receptor at 100 K 3.8 
5D6L beta2AR-T4L—CIM 3.2 
5JQH 




Structure of beta2 adrenoceptor bound to carazolol and an intracellular allosteric antago-
nist 
2.7 
6E67 Structure of beta2 adrenergic receptor fused to a Gs peptide 3.7 
6MXT Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71 3 
6N48 
Structure of beta2 adrenergic receptor bound to BI167107, Nanobody 6B9, and a positive 
allosteric modulator 
3.2 
6NI3 B2V2R-Gs protein subcomplex of a GPCR-G protein-beta-arrestin mega-complex 3.8 
6OBA The beta2 adrenergic receptor bound to a negative allosteric modulator 3.1 
6PRZ XFEL beta2 AR structure by ligand exchange from Alprenolol to Alprenolol. 2.8 
6PS0 XFEL beta2 AR structure by ligand exchange from Alprenolol to Carazolol. 3.4 
6PS1 XFEL beta2 AR structure by ligand exchange from Alprenolol to Timolol. 3.2 
6PS2 XFEL beta2 AR structure by ligand exchange from Timolol to Alprenolol. 2.4 
6PS3 XFEL beta2 AR structure by ligand exchange from Timolol to Carvedilol. 2.5 
6PS4 XFEL beta2 AR structure by ligand exchange from Timolol to ICI-118551. 2.6 
6PS5 XFEL beta2 AR structure by ligand exchange from Timolol to Propranolol. 2.9 
6PS6 XFEL beta2 AR structure by ligand exchange from Timolol to Timolol. 2.7 
7BZ2 
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Table A2. A list of all family B structures used in Figure 4. Included are the PDB code, description, and resolution in 
Ångströms. Structure 6FJ3 was not included in analyses due to unusable annotation and 6ORV was not included due to 
PDB unavailability. 
PDB Code Description Resolution, Å 
4K5Y 
Crystal structure of human corticotropin-releasing factor receptor 1 (CRF1R) in complex 
with the antagonist CP-376395 
2.98 
4L6R Structure of the class B human glucagon G protein coupled receptor 3.3 
4Z9G 
Crystal structure of human corticotropin-releasing factor receptor 1 (CRF1R) in complex 








Crystal structure of thermostabilised full-length GLP-1R in complex with a truncated 
peptide agonist at 3.7 A resolution 
3.7 
5UZ7 
Volta phase plate cryo-electron microscopy structure of a calcitonin receptor-heterotri-
meric Gs protein complex 
4.1 
5VAI 
Cryo-EM structure of the activated Glucagon-like peptide-1 receptor in complex with G 
protein 
4.1 
5VEW Structure of the human GLP-1 receptor complex with PF-06372222 2.7 
5VEX Structure of the human GLP-1 receptor complex with NNC0640 3 
5XEZ Structure of the Full-length glucagon class B G protein-coupled receptor 3 
5XF1 Structure of the Full-length glucagon class B G protein-coupled receptor 3.19 
5YQZ Structure of the glucagon receptor in complex with a glucagon analogue 3 
6B3J 
3.3 angstrom phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 re-
ceptor-Gs complex 
3.3 
6E3Y Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor 3.3 
6FJ3 
High resolution crystal structure of parathyroid hormone 1 receptor in complex with a 
peptide agonist 
2.5 
6KJV Structure of thermal-stabilised(M9) human GLP-1 receptor transmembrane domain 2.8 
6KK1 Structure of thermal-stabilised(M8) human GLP-1 receptor transmembrane domain 2.8 
6KK7 Structure of thermal-stabilised(M6) human GLP-1 receptor transmembrane domain 3.1 
6LMK Cryo-EM structure of the human glucagon receptor in complex with Gs 3.7 
6LML Cryo-EM structure of the human glucagon receptor in complex with Gi1 3.9 
6LN2 




Cryo-EM structure of the human PAC1 receptor coupled to an engineered heterotrimeric 
G protein 
3.9 
6M1H CryoEM structure of human PAC1 receptor in complex with maxadilan 3.6 
6M1I CryoEM structure of human PAC1 receptor in complex with PACAP38 3.5 
6NBF 
Cryo-EM structure of parathyroid hormone receptor type 1 in complex with a long-acting 
parathyroid hormone analog and G protein 
3 
6NBH 
Cryo-EM structure of parathyroid hormone receptor type 1 in complex with a long-acting 
parathyroid hormone analog and G protein 
3.5 
6NBI 
Cryo-EM structure of parathyroid hormone receptor type 1 in complex with a long-acting 
parathyroid hormone analog and G protein 
4 
6NIY 
A high-resolution cryo-electron microscopy structure of a calcitonin receptor-heterotri-
meric Gs protein complex 
3.34 
6ORV Non-peptide agonist (TT-OAD2) bound to the Glucagon-Like peptide-1 (GLP-1) Receptor 3 
6P9X CRF1 Receptor Gs GPCR protein complex with CRF1 peptide 2.9 
6P9Y PAC1 GPCR Receptor complex 3 




Cryo-EM structure of Urocortin 1-bound Corticotropin-releasing factor 1 receptor in com-
plex with Gs protein and Nb35 
3 
6PB1 
Cryo-EM structure of Urocortin 1-bound Corticotropin-releasing factor 2 receptor in com-
plex with Gs protein and Nb35 
2.8 
6UUN 








CryoEM Structure of the active Adrenomedullin 2 receptor G protein complex with adre-
nomedullin 2 peptide 
2.3 
6VCB 
Cryo-EM structure of the Glucagon-like peptide-1 receptor in complex with G protein, 
GLP-1 peptide and a positive allosteric modulator 
3.3 
6WHC CryoEM Structure of the glucagon receptor with a dual-agonist peptide 3.4 
6WI9 Human secretin receptor Gs complex 4.3 
6WPW GCGR-Gs signaling complex bound to a designed glucagon derivative 3.1 
6WZG Human secretin receptor Gs complex 2.3 
6X18 GLP-1 peptide hormone bound to Glucagon-Like peptide-1 (GLP-1) Receptor 2.1 
6X19 Non peptide agonist CHU-128, bound to Glucagon-Like peptide-1 (GLP-1) Receptor 2.1 
6X1A Non peptide agonist PF-06882961, bound to Glucagon-Like peptide-1 (GLP-1) Receptor 2.5 
6XOX cryo-EM of human GLP-1R bound to non-peptide agonist LY3502970 3.1 
7C2E GLP-1R-Gs complex structure with a small molecule full agonist 4.2 
7CZ5 
Cryo-EM structure of the human growth hormone-releasing hormone receptor-Gs pro-
tein complex 
2.6 
7D68 Cryo-EM structure of the human glucagon-like peptide-2 receptor-Gs protein complex 3 
7D76 Cryo-EM structure of the beclomethasone-bound adhesion receptor GPR97-Go complex 3.1 
7D77 Cryo-EM structure of the cortisol-bound adhesion receptor GPR97-Go complex 2.9 
7D3S Human SECR in complex with an engineered Gs heterotrimer 2.9 
7LCI PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R):Gs complex 2.9 
7LCJ PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R):Gs complex 2.82 
7LCK PF 06882961 bound to the glucagon-like peptide-1 receptor (GLP-1R) 3.24 
7KNT CryoEM structure of the apo-CGRP receptor in a detergent micelle 3.2 
7KNU CryoEM structure of the CGRP receptor with bound CGRP peptide in a detergent micelle 3.5 
Table A3. A list of all orexin receptor structures used in Figure 5. Included are the PDB code, description, and resolution 
in Ångströms. 
PDB Code Description Resolution, Å 
4S0V 
Crystal structure of the human OX2 orexin receptor bound to the insomnia drug Su-
vorexant 
2.5 
4ZJ8 Structures of the human OX1 orexin receptor bound to selective and dual antagonists 2.75 
4ZJC Structures of the human OX1 orexin receptor bound to selective and dual antagonists 2.83 
5WQC 
Crystal structure of human orexin 2 receptor bound to the selective antagonist EMPA de-
termined by the synchrotron light source at SPring-8. 
1.96 
5WS3 
Crystal structures of human orexin 2 receptor bound to the selective antagonist EMPA 
determined by serial femtosecond crystallography at SACLA 
2.3 
6TO7 Crystal structure of the Orexin-1 receptor in complex with suvorexant at 2.29 A resolution 2.26 
6TOD Crystal structure of the Orexin-1 receptor in complex with EMPA 2.11 
6TOS Crystal structure of the Orexin-1 receptor in complex with GSK1059865 2.13 
6TOT Crystal structure of the Orexin-1 receptor in complex with lemborexant 2.22 
6TP3 Crystal structure of the Orexin-1 receptor in complex with daridorexant 3.04 
6TP4 Crystal structure of the Orexin-1 receptor in complex with ACT-462206 3.01 
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6TP6 Crystal structure of the Orexin-1 receptor in complex with filorexant 2.34 
6TPG Crystal structure of the Orexin-2 receptor in complex with EMPA at 2.74 A resolution 2.74 
6TPJ Crystal structure of the Orexin-2 receptor in complex with suvorexant at 2.76 A resolution 2.74 
6TPN Crystal structure of the Orexin-2 receptor in complex with HTL6641 at 2.61 A resolution 2.61 
6TQ4 Crystal structure of the Orexin-1 receptor in complex with Compound 16 2.3 
6TQ6 Crystal structure of the Orexin-1 receptor in complex with Compound 14 2.55 
6TQ7 Crystal structure of the Orexin-1 receptor in complex with SB-334867 2.66 
6TQ9 Crystal structure of the Orexin-1 receptor in complex with SB-408124 2.65 
6V9S Structure-based development of subtype-selective orexin 1 receptor antagonists 3.5 
7L1U 
Orexin Receptor 2 (OX2R) in Complex with G Protein and Natural Peptide-Agonist 
Orexin B (OxB) 
3.2 
7L1V 
Orexin Receptor 2 (OX2R) in Complex with G Protein and Small-Molecule Agonist Com-
pound 1 
3 
Table A4. A list of all adenosine A2a receptor (A2AR) structures used in Figure 6. Included are the PDB code, description, 
and resolution in Ångströms. 
PDB Code Description Resolution, Å 
2YDO Thermostabilised HUMAN A2a Receptor with adenosine bound 3 
2YDV Thermostabilised HUMAN A2a Receptor with NECA bound 2.6 
3EML The 2.6 A Crystal Structure of a Human A2A Adenosine Receptor bound to ZM241385 2.6 
3PWH Thermostabilised Adenosine A2A Receptor 3.3 
3QAK Agonist bound structure of the human adenosine A2a receptor 2.71 
3REY Thermostabilised adenosine A2A receptor in complex with XAC 3.31 
3RFM Thermostabilised adenosine A2A receptor in complex with caffeine 3.6 
3UZA 








Crystal structure of human adenosine A2A receptor with an allosteric inverse-agonist an-
tibody at 2.7 A resolution 
2.7 
3VGA 
Crystal structure of human adenosine A2A receptor with an allosteric inverse-agonist an-
tibody at 3.1 A resolution 
3.1 
4EIY 
Crystal structure of the chimeric protein of A2aAR-BRIL in complex with ZM241385 at 
1.8A resolution 
1.8 
4UG2 Thermostabilised HUMAN A2a Receptor with CGS21680 bound 2.6 
4UHR Thermostabilised HUMAN A2a Receptor with CGS21680 bound 2.6 
5G53 Structure of the adenosine A2A receptor bound to an engineered G protein 3.4 
5IU4 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with ZM241385 at 1.7A resolution 
1.72 
5IU7 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with compound 12c at 1.9A resolution 
1.9 
5IU8 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with compound 12f at 2.0A resolution 
2 
5IUA 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with compound 12b at 2.2A resolution 
2.2 
5IUB 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with compound 12x at 2.1A resolution 
2.1 
5JTB Crystal structure of the chimeric protein of A2aAR-BRIL with bound iodide ions 2.8 
5K2A 2.5 angstrom A2a adenosine receptor structure with sulfur SAD phasing using XFEL data 2.5 
5K2B 2.5 angstrom A2a adenosine receptor structure with MR phasing using XFEL data 2.5 




1.9 angstrom A2a adenosine receptor structure with sulfur SAD phasing and phase exten-
sion using XFEL data 
1.9 
5K2D 1.9A angstrom A2a adenosine receptor structure with MR phasing using XFEL data 1.9 
5MZJ 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with theophylline at 2.0A resolution 
2 
5MZP 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with caffeine at 2.1A resolution 
2.1 
5N2R 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with PSB36 at 2.8A resolution 
2.8 
5NLX 
A2A Adenosine receptor room-temperature structure determined by serial millisecond 
crystallography 
2.14 
5NM2 A2A Adenosine receptor cryo structure 1.95 
5NM4 




















Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.9A obtained from be-
spoke co-crystallisation experiments. 
1.9 
5OM1 
Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 2.1A obtained from in 
meso soaking experiments (1 hour soak). 
2.1 
5OM4 
Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.86A obtained from in 
meso soaking experiments (24 hour soak). 
2 
5UIG 




Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals us-
ing Synchrotron Radiation 
3.2 
5VRA 2.35-Angstrom In situ Mylar structure of human A2A adenosine receptor at 100 K 2.35 
5WF5 Agonist bound human A2a adenosine receptor with D52N mutation at 2.60 A resolution 2.6 
5WF6 Agonist bound human A2a adenosine receptor with S91A mutation at 2.90 A resolution 2.9 
6AQF 
Crystal structure of A2AAR-BRIL in complex with the antagonist ZM241385 produced 
from Pichia pastoris 
2.51 
6GDG Cryo-EM structure of the adenosine A2A receptor bound to a miniGs heterotrimer 4.11 
6GT3 Crystal Structure of the A2A-StaR2-bRIL562 in complex with AZD4635 at 2.0A resolution 2 
6JZH 
Structure of human A2A adenosine receptor in complex with ZM241385 obtained from 
SFX experiments under atmospheric pressure 
2.25 
6LPJ A2AR crystallized in EROCOC17+4, LCP-SFX at 277 K 1.8 
6LPK A2AR crystallized in EROCOC17+4, LCP-SFX at 293 K 1.8 
6LPL A2AR crystallized in EROCOC17+4, SS-ROX at 100 K 2 
6MH8 
High-viscosity injector-based Pink Beam Serial Crystallography of Micro-crystals at a 
Synchrotron Radiation Source 
4.2 
6PS7 XFEL A2aR structure by ligand exchange from LUF5843 to ZM241385. 1.85 
6S0L 
Structure of the A2A adenosine receptor determined at SwissFEL using native-SAD at 
4.57 keV from all available diffraction patterns 
2.65 




Structure of the A2A adenosine receptor determined at SwissFEL using native-SAD at 
4.57 keV from 50,000 diffraction patterns 
2.65 
6WQA 




Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with Chromone 4d 
1.92 
6ZDV 
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex 
with Chromone 5d 
2.13 
7ARO 
Crystal structure of the non-ribose partial agonist LUF5833 bound to the adenosine A2A 
receptor 
3.12 
Table A5. A list of all β1-adrenergic receptor (β1AR) receptor structures used in Figure 6. Included are the PDB code, 
description, and resolution in Ångströms. 
PDB Code Description Resolution, Å 
2VT4 




Turkey Beta1 Adrenergic Receptor With Stabilising Mutations And Bound Partial Ago-
nist Dobutamine (Crystal Dob92) 
2.5 
2Y01 
Turkey Beta1 Adrenergic Receptor With Stabilising Mutations And Bound Partial Ago-
nist Dobutamine (Crystal Dob102) 
2.6 
2Y02 




























Thermostabilised turkey beta1 adrenergic receptor with 4-(piperazin-1- yl)-1H-indole 
bound (compound 19) 
2.8 
3ZPR 








Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist 
carvedilol 
2.3 
4BVN Ultra-thermostable beta1-adrenoceptor with cyanopindolol bound 2.1 
4GPO Oligomeic Turkey Beta1-Adrenergic G Protein-Coupled Receptor 3.5 
5A8E 




Ligand occupancy in crystal structure of beta1-adrenergic receptor previously submit-
ted by Huang et al. 
3.35 
6H7J 
Activated Turkey Beta1 Adrenoceptor With Bound Agonist Isoprenaline And Nano-
body Nb80 
2.8 
















Activated Turkey Beta1 Adrenoceptor With Bound Weak Partial Agonist Cyanopindo-
lol And Nanobody Nb6b9 
2.8 
6IBL 




Phosphorylated turkey beta1 adrenoceptor with bound agonist formoterol coupled to 
arrestin-2 in lipid nanodisc. 
3.3 
7BTS Structure of human beta1 adrenergic receptor bound to epinephrine and nanobody 6B9 3.1 
7BU6 
Structure of human beta1 adrenergic receptor bound to norepinephrine and nanobody 
6B9 
2.7 
7BU7 Structure of human beta1 adrenergic receptor bound to BI-167107 and nanobody 6B9 2.6 
7BVQ 
Crystal structure of 3-hydroxyanthranilate-3,4-dioxygenase N27A from Cupriavidus 
metallidurans in complex with 4-Cl-3-HAA 
2.5 
7JJO 
















Figure A1. Supplementary graphs to support Figure 3. (a) Generalised Procrustese transformation, (b) PC1 variation and 
(c) eigenvalues for the extracellular face of the β2AR receptors. (d) Generalised Procrustese transformation, (e) PC1 varia-
tion and (f) eigenvalues for the intracellular face of the β2AR receptors. 











Figure A2. Supplementary graphs to support Figure 4. (a) Generalised Procrustese transformation, (b) PC1 variation and 
(c) eigenvalues for the extracellular face of the family B receptors. (d) Generalised Procrustese transformation, (e) PC1 
variation and (f) eigenvalues for the intracellular face of the family B receptors. 










Figure A3. Supplementary graphs to support Figure 5. (a) Generalised Procrustese transformation, (b) PC1 variation and 
(c) eigenvalues for the extracellular face of the orexin receptors. (d) Generalised Procrustese transformation, (e) PC1 vari-
ation and (f) eigenvalues for the intracellular face of the orexin receptors. 
  











Figure A4. Supplementary graphs to support Figure 6. (a) Generalised Procrustese transformation, (b) PC1 variation and 
(c) eigenvalues for the extracellular face of the A2AR, β1AR and β2AR receptors. (d) Generalised Procrustese transfor-
mation, (e) PC1 variation and (f) eigenvalues for the intracellular face of the A2AR, β1AR and β2AR receptors. 
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